Choosing the Right PSMA PET Tracer: A Practical Guide to Clinical and Operational Factors

Review of prostate-specific membrane antigen (PSMA) PET radiopharmaceuticals—including 68Ga-PSMA-11 and 18F-DCFPyL—covers clinical indications, protocol considerations, and workflow logistics for prostate cancer imaging.

• Educational review of currently available PSMA-targeted PET tracers and their clinical roles.
• Discusses practical aspects: patient preparation, acquisition timing, billing, and departmental integration.
• Intended as a guide to help practices select and implement the most appropriate PSMA PET agent.

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.